Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24132| Title: | Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question | Authors: | BURZYKOWSKI, Tomasz Saad, Everardo D. BUYSE, Marc |
Issue Date: | 2017 | Publisher: | AMER MEDICAL ASSOC | Source: | JAMA ONCOLOGY, 3(3), p. 416-416 | Notes: | [Burzykowski, Tomasz; Saad, Everardo D.] Int Inst Drug Dev, 30 Ave Provinciale, B-1340 Louvain La Neuve, Belgium. [Burzykowski, Tomasz; Buyse, Marc] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Hasselt, Belgium. [Saad, Everardo D.] Dendrix Res, Sao Paulo, Brazil. [Buyse, Marc] Int Inst Drug Dev, San Francisco, CA USA. | Document URI: | http://hdl.handle.net/1942/24132 | ISSN: | 2374-2437 | e-ISSN: | 2374-2445 | DOI: | 10.1001/jamaoncol.2016.3941 | ISI #: | 000397491400023 | Rights: | (c) 2017 American Medical Association. All rights reserved. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2018 |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| burzykowski2016.pdf | Published version | 36.91 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
1
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
3
checked on Apr 22, 2024
Page view(s)
84
checked on Sep 6, 2022
Download(s)
254
checked on Sep 6, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.